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Abstract 
 
Objective. Recent technological advances have led to a rapid increase in alternative 
listening devices to conventional hearing aids. The aim was to systematically review the 
existing evidence to assess the effectiveness of alternative listening devices in adults with 
mild and moderate hearing loss. 
Design. A systematic search strategy of the scientific literature was employed, 
reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-
analyses (PRISMA) checklist.  
Study sample. Eleven studies met eligibility for inclusion: two studies evaluated 
personal sound amplification products, and nine studies assessed remote microphone systems 
(frequency modulation, Bluetooth, wireless).  
Results. The evidence in this review suggests that alternative listening devices 
improve behavioural measures of speech intelligibility relative to unaided and/or aided 
conditions. Evidence for whether alternative listening devices improve self-reported 
outcomes is inconsistent. The evidence was judged to be of poor to good quality and subject 
to bias due to limitations in study design. 
Conclusions. Our overall recommendation is that high-quality evidence (i.e. 
randomised controlled trials) is required to demonstrate the effectiveness of alternative 
listening devices. Such evidence is not currently available and is necessary to guide 
healthcare commissioners and policymakers when considering new service delivery models 
for adults with hearing loss.  
 
Review registration. Prospective Register of Systematic Reviews (PROSPERO), 
CRD4201502958. 
  
Introduction 
 
Acoustic amplification provided by hearing aids is currently the primary clinical management 
strategy for adults with mild and moderate hearing loss. Hearing aids have been shown to 
improve hearing-specific health-related quality of life, general health-related quality of life, 
and listening abilities (Ferguson et al., 2017). However, two out of three people who would 
benefit from using hearing aids do not take them up (Davis et al., 2007). For those who do 
obtain hearing aids, estimates of non-use vary from 3% to 24% (Ferguson et al., 2017). 
People with hearing loss report that they are concerned or embarrassed that hearing aids will 
make them look old and that they will be treated differently by others (Barker et al., 2017; 
Heffernan et al., 2016; Wallhagen, 2010). For these reasons, alternative devices to hearing 
aids and alternative service delivery models should be considered as a potential means to 
increase patient choice, accessibility to and acceptability of hearing services for people with 
hearing loss that currently do not, or cannot, access hearing aids. 
 
Whether new technologies can replace hearing aids has been ranked by patients and the 
public as the fifth topmost research priority for adults with mild to moderate hearing loss 
(Henshaw et al., 2015). Indeed, advances in technology have led to a rapid increase of 
alternative devices to conventional hearing aids. Here, we define alternative listening devices 
as standalone products that provide amplification of sound (e.g. Smartphone hearing aid 
applications; personal sound amplification products; hearables), as well as assistive listening 
devices (ALDs) that amplify and transmit sound directly into hearing aids (e.g. Smartphone-
connected hearing aids; remote microphone systems). Many alternative listening devices can 
link wirelessly to Smartphone technologies, allowing users to adjust and personalise their 
hearing settings (e.g. gain, frequency response) in different listening situations at their own 
  
convenience via an application (or app), and without the need to visit a qualified clinician 
(Taylor, 2015).  
 
Existing evidence is mixed in terms of whether alternative listening devices are a suitable 
management strategy for hearing loss. For example, ‘mid-range’ (US$100-$500) personal 
sound amplification products (PSAPs), a type of ‘direct-to-consumer’ hearing device, have 
been shown to provide comparable electroacoustic characteristics (i.e. meet gain and output 
targets using National Acoustic Laboratories prescriptive procedures) to hearing aids 
(Callaway & Punch, 2008). By comparison, other products defined as ‘low-cost’ (<US$100) 
may be of limited benefit and potentially damaging to residual hearing due to over-
amplification (Callaway & Punch, 2008; Chan & McPherson, 2015). Smartphone-based 
‘hearing aid’ apps have also been shown to provide similar levels of amplification, improved 
speech-in-noise performance, and greater self-reported benefit in comparison to hearing aids 
(Amlani et al., 2013). Remote microphone systems have also been shown to improve hearing 
outcomes, but may require additional audiological support for optimal use (Boothroyd, 2004).  
 
To date, no systematic review has evaluated whether alternative listening devices are a 
clinically effective intervention for people with mild and moderate hearing loss. A systematic 
review with meta-analysis provides the gold-standard evidence-base to inform future 
feasibility and effectiveness trials of alternative listening devices. This approach is consistent 
with the Medical Research Council’s guidelines for evaluating complex healthcare 
interventions (Medical Research Council, 2006). The primary objective of this study, 
therefore, was to review and synthesise the existing body of evidence to assess the 
effectiveness of alternative listening devices to conventional hearing aids. 
 
  
Methods 
 
Prior to commencing the systematic review, the protocol was registered with the International 
Prospective Register of Systematic Reviews (PROSPERO) (registration number, 
CRD42015029582) and published in a peer-reviewed publication (Maidment et al., 2016). 
Methods are reported according to the Preferred Reporting Items for Systematic reviews and 
Meta-analyses (PRISMA) checklist (Moher et al., 2009).  
 
Eligibility criteria 
The criteria for inclusion in the review were specified in terms of participants, intervention, 
comparators, outcomes, and study designs (PICOS) as follows:  
 
Participants 
Adults (≥18 years) with a mild and moderate hearing loss (average hearing threshold across 
octave frequencies 0.25-4 kHz ≥20 and ≤70 dB HL (British Society of Audiology, 2011). 
Studies that included both children (<18 years) and adults were not included unless data were 
reported separately. If the hearing thresholds were not specified, the study author was 
contacted for further clarification. If hearing threshold data was not reported and could not be 
obtained, studies were included where the mean average hearing threshold reported fell 
within the range of either mild (between 20 to 40 dB HL) or moderate hearing loss (between 
41 to 70 dB HL). Bilateral and unilateral sensorineural, conductive and mixed hearing losses 
were included.  
 
 
 
  
Intervention(s)  
An alternative listening device to a conventional hearing aid was considered to be non-
medical standalone product (e.g. Smartphone app, PSAP, hearable) or an assistive listening 
device that provides additional functionality to a conventional hearing aid (e.g. remote 
microphone system; Smartphone-connected hearing aid whereby the Smartphone can be used 
as a remote microphone and/or allows manipulation of gain and frequency response via an 
app). An alternative listening device should aim to improve hearing and communication 
outcomes in people with hearing loss, specifically via the amplification of external sound 
sources.  
 
Comparators 
The comparisons of interest were either passive (e.g. unaided) or active control (e.g. 
conventional hearing aid). A conventional hearing aid was defined as a device that detects 
and amplifies sound, delivering an amplified acoustic signal via air conduction to the external 
auditory canal on the same side that the signals are detected, irrespective of where it is worn 
(behind-the-ear, in-the-ear or receiver-in-the-canal). Studies evaluating analogue hearing aids 
were excluded. 
 
Outcomes  
As the aim of the review was to assess the clinical-effectiveness of alternative listening 
devices, studies were restricted to outcomes associated with the consequences of hearing loss. 
There were no restrictions as to the duration of follow-up. Primary outcomes included one or 
more of the following: (i) behavioural measures of speech intelligibility (e.g. intelligibility of 
syllables, words or sentences presented in quiet or in noise); (ii) hearing-specific health-
related quality of life (QoL), where participation was the key domain, measured using any 
  
self-reported questionnaire (e.g. Hearing Handicap Inventory for the Elderly: Ventry & 
Weinstein, 1982); and (iii) adverse effects of patient, reported as pain, discomfort, tenderness, 
skin irritation or ear infection as a consequence of device fitting. Secondary outcomes 
included any of the following self-reported outcomes: (i) General health-related QoL (e.g. 
Health Utilities Index Mark 3: Furlong et al., 2001); (ii) listening ability (e.g. Abbreviated 
Profile of Hearing Aid Benefit: Cox & Alexander, 1995); (iii) cognition (e.g. working 
memory); (iv) feasibility (e.g. usability, adherence); (v) adverse effect of noise-induced 
hearing loss (e.g. due to over-amplification from inappropriate hearing aid fitting). 
 
Study designs 
Retrospective or prospective studies, randomised controlled trials, non-randomised controlled 
trials, before and after studies were included. Articles reporting expert opinions, practice 
guidelines, case reports, case series, conference abstracts and book chapters were excluded.  
 
Search strategy 
An initial literature search was conducted by a medical information specialist (Farhad 
Shokraneh, University of Nottingham) on April 2nd 2016. Searches were last updated on 
March 7th 2018 to ensure that any newly published studies were included. The following 
databases were searched: CINAHL (via EBSCO host), Cochrane Library, EMBASE (via 
Ovid SP), MEDLINE (via Ovid SP), PubMed, Scopus, Citations Indexes of Web of Science, 
ISRCTN Registry, ClinicalTrials.Gov, and WHO International Clinical Trials Registry 
Platform. Supplemental 1 provides full electronic search strategies for all databases. All 
database searches were completed in one day and with no time, language, document type, or 
publication status limitations. The search terms were collected based on free text and 
  
controlled vocabularies (Medical Subject Headings, Excerpta Medica Tree, and CINHAL 
Headings), expert opinion, literature review, and checking the test search results.  
 
Additional information was identified manually through snowballing of the reference lists 
from included studies, as well as screening of related articles by shortlisted authors to identify 
any relevant articles that may not have been returned by the initial database searches. Contact 
with study authors was not necessary to ascertain whether any studies were ongoing. 
 
Study selection 
Two investigators (DM, AB) independently screened all identified references to decide 
eligibility according to the PICOS criteria by reading the title and/or abstract. The full text 
was obtained for articles that appeared to meet eligibility or where there was any uncertainty 
(i.e. insufficient information to make a clear decision). We did not need to contact study 
authors for additional information to resolve questions concerning eligibility. Discrepancies 
were resolved through discussion between investigators.   
 
Data collection process 
A standardised data collection form constructed via Covidence (www.covidence.org) was 
used, which included study details (e.g. sponsorship source, country, setting), author’s 
contact details (name, institution, email, postal address), study design, population 
(inclusion/exclusion criteria, baseline characteristics), interventions (and comparators), and 
outcomes. Prior to starting the review, detailed guidance notes were devised by DM and were 
piloted by DM and AB to ensure consistency. Data collection was conducted by DM and AB 
independently, but in duplicate for every included record. Where necessary, study authors 
were contacted to resolve any uncertainties and to obtain any missing data. If data could not 
  
be obtained and were only presented in graphical form, the results were estimated from 
figures using WebPlotDigitizer (http://arohatgi.info/WebPlotDigitizer/app/). Disagreements 
about numerical data extracted from figures were discussed and resolved by averaging. 
 
Risk of bias in individual studies 
DM and AB independently assessed risk of bias of each included study with the Cochrane 
risk of bias tool (Higgins & Green, 2011), which rates the studies as ‘high risk’, ‘low risk’ or 
‘unclear risk’ in the following six domains: sequence generation, allocation concealment, 
blinding of participants and personnel, blinding outcome assessors, incomplete outcome data, 
selective outcome reporting, and other sources of bias (e.g. influence of funders). As all 
included studies were non-randomised, the Downs and Black (1998) checklist, which consists 
of 27 criteria, was used to assess study quality. Criterion 27 was adapted to consider whether 
or not a power calculation was performed rather than whether there was sufficient power to 
detect a clinically meaningful change, as there is a lack of consensus regarding clinically 
meaningful change in hearing loss outcome measurement (Barker et al., 2016). All answers 
were scored 0 (‘no’ or ‘unable to determine) or 1 (‘yes’), with the exception of criterion 5 
(‘Are the distributions of principal confounders in each group of subjects to be compared 
clearly described?’), which was scored 0 (‘no’), 1 (‘partially’) or 2 (‘yes’). The total 
maximum score was 28, with study quality rated as excellent (26-28), good (20-25), fair (15-
19) or poor (14) (Hooper et al., 2008).   
 
Data synthesis  
Included studies were reviewed in order to determine whether their data were suitable for 
inclusion in the meta-analyses. Meta-analyses were only performed when studies were 
broadly comparable in terms of study design, interventions, and outcomes. For continuous 
  
data, where the studies used the same outcome measure, mean differences (MDs) were 
calculated with 95% confidence intervals (CI). If different outcome measures were employed, 
effect sizes were calculated as standardised mean differences (SMDs) in which the mean 
difference between conditions was divided by the pooled standard deviation (between-group) 
or by the standard deviation of the differences (within-group). Heterogeneity in effect sizes 
across studies was examined using the I2 statistic and its significance was tested using a χ2 
test. This approach to quantifying heterogeneity provided a value from 0 to 100%, with low 
(0%-40%), medium (41%-60%), and high (61%-100%) ranges (Higgins & Green, 2011). In 
the absence of meta-analysis, primary and secondary outcomes were assessed at the 
individual study level through narrative synthesis (Popay et al., 2006).   
 
Deviations from the published protocol 
Although we pre-specified that the data would be subjected to both random and fixed effects 
models, we opted to only use a random-effects meta-analysis. A random effects approach was 
considered most appropriate based on an assumption that effect sizes would vary across 
studies, not only because they used different samples of participants (as assumed in a fixed 
effect approach) but also due to differences in assessment methodologies employed. In 
addition, we stated previously that we would not pool studies if I2 exceeded 60%, suggestive 
of high heterogeneity (Higgins & Thompson, 2002). However, although heterogeneity was 
high, which was to be expected due to differences across studies, we thought it useful to 
illustrate the pooled data for comparable studies irrespective of heterogeneity, but took this 
into account when interpreting the data.  
 
 
 
  
Results 
 
A total of 2,198 records were identified for screening. Following the removal of 1,060 
duplicate publications, 1,138 records were subjected to a three-stage screening process 
(Figure. 1). The full texts of 149 articles that passed the initial title and abstract screen were 
retrieved. A total of 138 articles were not judged to have met inclusion criteria and were 
excluded. Eleven studies were included in the review. 
 
Supplemental 2 summarises the characteristics of the 11 studies included in the review. Two 
categories of alternative listening device (i.e. intervention) were evaluated, (i) PSAPs (n=2); 
and (ii) remote microphone systems (n=9). All studies were before-after comparisons, with 
participants acting as their own control. Comparators included unaided, conventional hearing 
aids alone, or another alternative listening device. Four studies assessed outcomes at a range 
of follow-up durations, from one month (Sacco et al., 2016) to one year (Chisolm et al., 
2007). For studies that were sufficiently similar in terms of interventions and outcomes, 
meta-analyses were performed. Narrative synthesis (Popay et al., 2006) are reported where 
meta-analyses were not possible.   
 
PSAPs  
 
Speech intelligibility 
Two eligible studies (n=73 participants) assessed six different PSAPs. Sacco et al. (2016) 
evaluated the TEO First listening device (Tinteo, Personal Sound Society), classified by the 
authors as an ‘over-the-counter’ hearing device. Reed et al. (2017) assessed five different 
PSAPs, which varied in terms of the purchase price as of 4th July 2017. 
  
PSAPs vs. unaided. Summary effects and forest plots are provided in Table 1 and 
Figure 2 respectively. Overall performance across both studies was better when using a PSAP 
relative to unaided conditions (Figure 2A). Heterogeneity was low (I2=0%). To provide a 
conservative estimate of effect, performance in Reed et al.’s (2017) study was pooled across 
all five included PSAPs. However, Reed et al. (2017) also showed that, in comparison to 
unaided, performance was superior for PSAPs that were priced ≥US$299.99 (Reed et al., 
2017).       
PSAPs vs. hearing aids. Only one study (n=42 participants) compared PSAPs with 
conventional hearing aids (Reed et al., 2017). This showed an effect favouring hearing aids 
compared to PSAPs that were priced ≤US$269.99. However, performance did not differ 
statistically between hearing aids and PSAPs that were priced ≥US$299.99.     
 
Hearing-specific health-related QoL  
Hearing-specific health-related QoL was only reported by Sacco et al (2016) (n=31 
participants), who administered the Glasgow Hearing Aid Benefit Profile (GHABP) handicap 
subscales. Handicap scores reported as percentage change, decreased for the TEO First 
device relative to unaided handicap for following two items, (i) having a conversation 
without background noise (-9.6 %, p=0.018), and (ii) having a conversation with several 
people (-16.2%, p=0.008).  
 
Listening ability  
Listening abilities were only reported by Sacco et al (2016), whereby statistically significant 
decreases in GHABP residual disability subscale scores (percentage change) were found for 
the TEO First device compared to unaided disability for the following four items: (i) 
watching television (-18.5%, p=0.011), (ii) having a conversation without background noise 
  
(-16.5%, p=0.002), (iii) having a conversation in noisy background (-17.1%, p=0.027), and 
(iv) having a conversation with several people (-20%, p=0.014). 
 
Feasibility  
Sacco et al. (2016) assessed device acceptability using a six-point Likert scale, from zero 
(‘worst’) to five (‘best’). Mean scores ranged from 1.8 (SD=1.4) for ‘satisfaction when using 
the noisy setting’, to 3.2 (SD=1.6) for ‘ease of use’. The authors conclude that overall 
acceptability of the TEO First device was low-to-moderate. Mean duration of use was also 
measured, with participants reporting average daily use of 60 minutes. Feasibility was not 
reported by Reed (2017). 
 
Adverse effects 
Sacco et al. (2016) explicitly reported that ‘no adverse events were observed’ during the 
course of the study. Adverse effects were not reported by Reed (2017). 
 
Remote microphone systems 
 
Speech intelligibility  
Six studies tested speech intelligibility. Summary effects and forest plots are provided in 
Table 1 and Figure 2 respectively. For all meta-analyses, heterogeneity was high (I2≥80.3%), 
and statistically significant (p≤0.024). 
Hearing aids+FM system vs. Unaided. Three studies (Lewis et al., 2004; Lewis et al., 
2010; Rodemerk & Galster, 2015) (n=61 participants) showed that performance favoured the 
hearing aids+FM system compared to unaided (Figure 2B).  
  
Hearing aids+FM system vs. Hearing aid alone. Two studies (Lewis et al., 2004; 
Rodemerk & Galster, 2015) (n=51 participants) showed that performance favoured the 
hearing aids+FM system compared to hearing aids alone (Figure 2C).  
Hearing aids+FM system vs. FM microphone only. Three studies (Rodemerk & 
Galster, 2015; Lewis et al., 2010; Norrix et al., 2016) (n=36 participants) showed that while 
performance favoured FM microphone only compared to hearing aids+FM system, the 
pooled effect was not significant (Figure 2D).  
Hearing aids+FM system vs. Hearing aids+2.4GHz system. Two studies (Rodemerk 
& Galster, 2015; Thibodeau, 2014) (n=27 participants) showed conflicting results, with one 
favouring hearing aids+FM (Rodemerk & Galster, 2015) and the other favouring hearing 
aids+2.4GHz system (Thibodeau, 2014) (Figure 2E). 
Hearing aids+Bluetooth system vs. Hearing aids alone. Two studies (Rodemerk & 
Galster, 2015; Kim et al., 2014) (n=46 participants) showed performance favoured the 
hearing aids+Bluetooth system relative to the when the hearing aid was used alone (Figure 
2F).  
Remote microphone only mode vs. Unaided or hearing aid alone. Only one study 
(n=16 participants) compared speech intelligibility across four different remote microphone 
systems (FM, Bluetooth, 900MHz wireless, 2.4GHz wireless) (Rodemerk & Galster, 2015). 
All systems in microphone-only mode significantly improved performance relative to both 
unaided and hearing aid alone conditions (p<0.001). The magnitude of this effect did not 
differ statically between systems.  
 
Hearing-specific health-related QoL   
There was no robust evidence as to whether remote microphone systems improved self-
reported hearing-specific health-related QoL. 
  
Hearing aids+FM system vs. Hearing aids alone. Only one study, using the 
MarkeTrak VI survey, compared the hearing aids+FM system and hearing aids alone 
(Chisolm et al., 2007). No statistically significant differences were found (six weeks, n=36, 
Z=0.68, p=0.499; one year, n=30, Z=0.71, p=0.489). 
Hearing aids+Bluetooth accessories vs. Hearing aids alone. Only one study (n=12 
participants), using the International Outcome Inventory for Hearing Aids (IOI-HA, Cox & 
Alexander, 2002), compared hearing aids+Bluetooth accessories to hearing aids alone (Smith 
& Davis, 2014). A statistically significant improvement favouring hearing aids+Bluetooth 
accessories was found for residual participation restrictions (Z=2.12, p=0.034).  
 
Listening ability 
There was no robust evidence as to whether remote microphone systems improved self-
reported listening abilities.  
Hearing aids+FM system vs. Hearing aids alone. Two studies (Chisolm et al., 2007; 
Lewis et al., 2005) (n=59 participants), using different variants of the Communication Profile 
for the Hearing Impaired (CPHI, Demorest & Erdman, 1987), showed that listening abilities 
were significantly better (p≤0.03) for the hearing aids+FM system compared to hearing aids 
alone for social, work, home situations.  
Hearing aids+Bluetooth accessories vs. Hearing aids alone. Only one study (n=12 
participants), using the IOI-HA, GHABP, and the Speech, Spatial and Qualities of Hearing 
Scale (SSQ, Gatehouse & Noble, 2004) (n=12 participants), compared listening abilities 
between hearing aids+Bluetooth accessories and hearing aids alone (Smith & Davis, 2014). 
Statistically significant improvements favouring hearing aids+Bluetooth accessories were 
found for residual activity limitations (Z=2.24, p =0.025) and residual disability (Z=2.55, 
p=0.011) subscales (IOI-HA, GHABP). No statistically significant differences (p≤0.374) 
  
across all sub-scales were found between conditions when listening abilities were measured 
using the SSQ. 
 
Feasibility  
Three different studies assessed the following feasibility domains: (i) satisfaction (Chisolm et 
al., 2007); (ii) preferences (Thibodeau, 2014); and (iii) usability (Smith & Davis, 2014).  
Hearing aids+FM system vs. Hearing aids alone. Using the MarkeTrak VI survey, 
Chisolm et al. (2007) found statistically significant improvements favouring the hearing 
aids+FM system for  satisfaction in ‘noisy’ listening situations (e.g. restaurant, large group, 
leisure activities) (six weeks, n=36, Z=3.10, p=0.002; one year, n=30, Z=2.27, p=0.007) and 
‘ability to hear soft sounds’ (six weeks, n=36, Z=3.31, p=0.001; one year, n=30, Z=3.25, 
p=0.001). .  
Hearing aids+FM system vs. Hearing aids+2.4GHz system. Thibodeau (2014) (n=10 
participants) found that all participants reported that they preferred using hearing 
aids+2.4GHz wireless system compared to hearing aids+FM system.  
Hearing aids+Bluetooth accessories vs. Hearing aids alone. Smith and Davis (2014) 
(n=12 participants) observed that the majority of participants (exact data not reported) 
reported that Bluetooth accessories ‘quite easy’ to use, and improved the quality of sound 
when viewing the TV and using a cell phone.  
 
Risk of bias assessment 
Using the Cochrane risk of bias tool (Higgins & Green, 2011), all studies were judged to be 
high risk with regard to selection bias (i.e. random sequence generation, allocation 
concealment) due to the nature of the before-after study design (Table 2). Risk of 
performance (blinding of participants/personnel) and detection bias (blinding of outcome 
  
assessment) was judged to be high for ten and eight studies respectively, as no blinding 
procedures were reported. Studies were judged to be low risk if blinding was stated, although 
it should be acknowledged that blinding in before-after studies is not always strictly possible 
as a consequence of this study design. The risk of attrition bias due to incomplete outcome 
data was judged to be low for all studies as there was no attrition in nine studies. In the 
remaining two studies, while attrition ranged from 16.67% (Chisolm et al., 2007) to 25% 
(Smith & Davis, 2014) at the one year and 12 week follow-up respectively, reasons for 
incomplete outcome data were considered to be clearly reported in each article, increasing 
confidence that missing data had no undue influence on the results. With the exception of 
Reed et al. (2017), risk of reporting bias (selective outcome reporting) was judged to be high 
for all studies, as numerical values were not sufficiently reported and/or were only provided 
for statistically significant results. In terms of risk of other bias, with the exception of three 
studies (Kim et al., 2014; Norrix et al., 2016; Reed et al., 2017), this was judged to be unclear 
for seven studies because of financial support from the manufacturer of the device(s) being 
evaluated. For one study (Smith & Davis, 2014), an author acted as a consultant for a hearing 
aid manufacturer. For these reasons, potential vested interest could have posed a threat to 
validity.  
 
Quality assessment 
Scores on the Downs and Black (1998) checklist ranged from 13 (Smith & Davis, 2014) to 21 
(Sacco et al., 2016) out of a possible total of 28, indicative of a poor to good level of quality 
respectively. In terms of ‘reporting’, with the exception of one study (Sacco et al., 2016), 
adverse effects as a consequence of the intervention were not reported by any study. Whether 
participants were representative of the target population from which they were recruited (i.e. 
‘external validity’) was also uncertain for the majority of study, as sufficient detail was often 
  
lacking to make a clear judgement. In terms of ‘internal validity’ (e.g. randomisation, 
blinding), lower quality ratings arose because no studies randomised participants to 
intervention groups. Furthermore, only one study attempted to blind study participants to the 
intervention they received (Thibodeau, 2014). Similarly, a power calculation was reported for 
only one study to determine sample size (Rodemerk & Galster, 2015).  
 
Discussion 
 
In the current review, the scientific literature examining the effectiveness of alternative 
listening devices in adults with mild to moderate hearing loss was systematically searched. 
Eleven studies met eligibility for inclusion, two studies evaluated PSAPs and nine assessed 
remote microphone systems (FM, Bluetooth, wireless). The majority of studies primarily 
examined behavioural measures of speech intelligibility in noise. Self-reported hearing-
specific QoL, listening ability, and feasibility (i.e. usability, adherence, acceptability) were 
also evaluated, but to a lesser extent. There were some outcomes of potential interest that 
were not measured (i.e. cognition, general health-related QoL, adverse effects). Follow-up 
ranged from one month (Sacco et al., 2016) to one year (Chisolm et al., 2007), with no long-
term follow-up greater than one year. There was considerable heterogeneity, whereby 
interventions and outcomes varied greatly across studies. The evidence was judged to be of 
poor to good quality, and subject to bias mainly due to limitations in study design. 
 
Speech intelligibility 
For speech intelligibility performance, data pooled across two studies demonstrated that there 
was a beneficial effect of PSAPs in improving performance compared to unaided conditions 
(Reed et al., 2017; Sacco et al., 2016). Findings reported by Reed et al. (2017) further suggest 
  
that this effect may be dependent on the cost of the PSAP assessed, whereby PSAPs that were 
priced ≥US$299.99 improved speech intelligibility performance relative to unaided, and did 
not differ statistically from hearing aids. A potential explanation for this finding may reside 
in existing evidence showing that higher priced PSAPs provide comparable electroacoustic 
characteristics to hearing aids (Callaway & Punch, 2008). However, the extent to which these 
variables (i.e. price and/or electroacoustic characteristics) impact patient-reported outcomes 
for PSAPs remains to be established.  
 
Similarly, speech intelligibility performance was superior for remote microphone systems 
used in conjunction with hearing aids (FM, Bluetooth, wireless) relative to both unaided and 
hearing aids alone (Kim et al., 2014; Lewis et al., 2004; Lewis et al., 2010; Norrix et al., 
2016; Rodemerk & Galster, 2015). While we can be confident in the direction of the effect, 
due to high heterogeneity, the pooled effect size estimates could change with further 
evidence. Heterogeneity between studies most likely arose as a consequence of differences in 
assessment methodologies. In future, there should be greater consistency in the outcome 
measures used to assess speech intelligibility in adults with hearing loss. Standardised 
measurement procedures should be employed across studies so that they can be appropriately 
combined to enable direct comparison of effect sizes.  
 
Self-reported hearing-specific QoL, listening abilities and feasibility 
Outcome measures used to assess self-reported hearing-specific QoL, listening abilities and 
feasibility varied considerably across studies, as did duration of follow-up. This not only 
limited direct comparison, but may also help to explain why the pattern of results was 
inconsistent across studies. On this basis, there is no robust evidence as to whether alternative 
listening devices included in this review improve these outcomes, or if the improvements 
  
observed are specific to the device, situations specified and/or outcome measures employed 
in each study. As a consequence, we suggest that the same self-report outcome measures 
should be consistently applied across studies, which should be appropriately sensitive and tap 
into the behavioural domains that they aim to reflect (Heinrich et al., 2016; Ferguson et al., 
2014; 2017). There is a clear need for the development of a core outcome set in audiological 
rehabilitation research (Barker et al., 2015; Ferguson et al., 2017). In addition, longer follow-
up durations greater than one-year would improve the certainty in the results, providing a 
better estimate of potential long-term benefit (Barker et al., 2016; Ferguson et al., 2017).  
 
Study quality and risk of bias 
The quality of the evidence included in this review was judged to be poor to good and subject 
to bias. The design of all studies was classified as ‘observational’ (i.e. before-after 
comparison), with no studies employing a separate control group. As a result, confidence in 
the effect size estimates are limited, as the true effects may be different. It cannot be known 
with certainty whether the effects seen are due to the devices, rather than due to regression to 
the mean or external factors affecting all participants. Further high-quality evidence is, 
therefore, required to improve confidence in the effect size estimates. 
 
It should be noted that no studies assessing Smartphone-connected hearing aids or 
Smartphone ‘hearing aid’ apps met the inclusion criteria during the article screening process. 
We are aware of at least one non-peer reviewed publication that has evaluated Smartphone 
hearing aid apps compared to conventional hearing aids (Amlani et al., 2013). This study was 
not detected in the current review because it was published in an industry-related magazine 
(i.e. the grey literature). Inclusion of the grey literature could have provided a broader review 
of the available evidence. However, we opted to exclude databases of the grey literature in 
  
our pre-specified search strategy because there is no agreed method of extracting and 
synthesising evidence obtained from this literature in a clear and transparent way. This would 
also reduce, though not eliminate, the likelihood of including poor quality studies. Two of the 
study authors (DM, MF) worked collaboratively with the UK NIHR Horizon Scanning and 
Intelligence Centre to review new and emerging technologies for hearing loss (NIHR Horizon 
Scanning Research & Intelligence Centre, 2017). Together with the current systematic 
review, and Cochrane review on hearing aids for mild to moderate hearing loss (Ferguson et 
al., 2017), all three reviews provide up-to-date high-level evidence of a wide range of 
listening devices. 
 
Review limitations 
A potential limitation of this review, as well as the field more generally, is that there is no 
consensus in terms of audiometric descriptors across different countries and organisations. In 
this review we used the audiometric descriptors for mild to moderate hearing loss, based on 
pure-tone air-conduction thresholds established by the British Society of Audiology (2011). 
An average hearing threshold in the better hearing ear across octave frequencies 0.25-4 kHz 
that are ≥20 and ≤40 dB HL is defined as ‘mild’, and ≥41 and  ≤70 dB HL as ‘moderate’. 
Other definitions adopt different frequency ranges and intensity cut-offs, such as the World 
Health Organisation definitions, whereby average thresholds across 0.5-4 kHz between 26 
and 40 dB HL is defined as ‘mild’, and 41 to 60 dB HL as ‘moderate’ hearing loss (Mathers 
et al., 2000). In addition, individual hearing threshold data were seldom reported for all 
included studies, and could not be made available by the study authors for logistical reasons. 
Although unlikely, included studies could have included some participants with more severe 
degrees of hearing loss. Nevertheless, in accordance with our published protocol (Maidment 
  
et al., 2016), studies were verified as eligible for inclusion because the mean average hearing 
threshold always fell within the pre-specified range.  
 
Research recommendations  
On the basis of this review, further high-quality evidence, namely randomised controlled 
trials (RCTs), is needed to evaluate whether alternative listening devices are a clinically- and 
cost-effective intervention for adults living with hearing loss. This is in-line with a research 
recommendation for hearing loss assessment and management specified by the UK National 
Institute for Clinical Excellence (2018). Such research has also been identified as a high-
priority need in the US (Humes et al., 2017; National Academies of Science, 2016), given 
that alternative listening devices could enable new service delivery models (e.g. direct-to-
consumer, over-the-counter). Moreover, there have been recent legislative changes in the 
United States, with the introduction of the Over-the-Counter (OTC) Hearing Aid Act of 2017, 
which aim to improve accessibility and affordability of hearing-healthcare for adults. High-
quality evidence, therefore, is needed as a priority in this area. In a recently published 
randomised, double-blind, placebo-controlled clinical trial (Humes et al., 2017), hearing aids 
fitted by an audiologist (i.e. ‘audiology best practices’) and hearing aids fitted using an OTC 
model resulted in similar effect sizes for measures of speech recognition and hearing aid 
benefit. Nevertheless, satisfaction and percentage likely to purchase hearing aids post-trial 
were lower for the OTC model, potentially attributable to the lack of audiological interaction 
during the provision of the hearing aids (Humes et al., 2017). It has been proposed that adults 
living with hearing loss may require optional assistance to successfully use alternative 
listening devices that do not require a hearing healthcare professional in terms of device 
fitting and/or fine-tuning (Keidser and Convery, 2016). In support, the results of our mixed-
methods usability study, completed following this systematic review, suggest that people 
  
living with hearing loss would like greater instruction to use and adjust alternative listening 
devices themselves (Maidment & Ferguson, 2017; in press). Remotely-delivered information 
is one means of providing such assistance, and has been shown to successfully supplement 
the provision of hearing aids, resulting in improved outcomes (Kramer et al., 2005; Ferguson 
et al., 2016; Thorén et al., 2014). Therefore, we recommend that this concept be incorporated 
in the design of future effectiveness trials.     
 
Conclusions 
In summary, the evidence included in this review suggests that alternative listening devices 
improve behavioural measures of speech intelligibility relative to unaided and/or 
conventional hearing aids. There is no robust evidence as to whether alternative listening 
devices improve self-reported outcomes. Furthermore, the evidence was judged to be poor to 
good quality and subject to bias due to limitations in study design. On this basis, we argue 
that high-quality studies (i.e. RCTs) investigating the clinical- and cost-effectiveness of 
alternative listening devices are needed in this area. Such evidence, though currently 
unavailable, is necessary to guide healthcare commissioners and policymakers when 
considering new service delivery pathways to benefit adults living with hearing loss. 
Moreover, given that this field is likely to continue to develop in new and unexpected ways, 
we envisage that the current systematic review will require updating, and it is our intention to 
do so in two to three years. These rapid developments reflect the innovative nature of the 
field, which not only has the potential to transform hearing healthcare service delivery in the 
future, but also increase the likelihood that people will seek and use amplification to 
successfully manage their hearing loss.   
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Table 1. Summary effects of speech intelligibility for comparable studies included in the 
review. CI = confidence interval; FM = frequency modulation; MD = mean 
difference; SMD = standardised mean difference. 
  
Study N MD/SMD 95% CI Z  p 
Heterogeneity 
χ2 (df) I2 
PSAPs vs. Unaided 
Reed et al (2017) 42 -0.24 -0.55, 0.06 - - - - 
Sacco et al (2016) 31 -0.41 -0.77, -0.04 - - - - 
Total 73 -0.31 -0.55, -0.07 -2.58 <0.01 
0.45 (1) 
p=0.503 
0% 
Hearing aids+FM system vs. Unaided 
Lewis et al (2004) 45 -25.10a -27.11, -23.09 - - - - 
Lewis et al (2010) 10 -8.60a -11.73, -5.47 - - - - 
Rodemerk & Galster (2015) 16 -14.80a -16.80, -12.80 - - - - 
Total  71 -16.22a -25.64, -6.81 -3.38 <0.001 
92.42 (2)  
p<0.001  
98% 
Hearing aids+FM system vs. Hearing aids alone 
Lewis et al (2004) 45 -20.44a -22.07, -18.81 - - - - 
Rodemerk & Galster (2015) 16 -14.00a -16.52, -11.48 - - - - 
Total 61 -17.29a -23.60, -10.99 -5.37 <0.001 
17.62 (1)  
p<0.001 
94.32% 
Hearing aids+FM system vs. FM-only mode 
Lewis et al (2010) 10 0.68 -0.01, 1.36 - - - - 
Norrix et al (2016) 10 2.80 1.42, 4.17 - - - - 
Rodemerk & Galster (2015) 16 0.36 -0.14, 0.87 - - - - 
Total  36  1.15 -0.22, 2.52 1.65 0.10 
10.62 (2) 
p<0.01   
89.43% 
Hearing aids+FM system vs. Hearing aids+2.4GHz system 
Rodemerk & Galster (2015) 16 -1.55 -2.28, -0.82 - - - - 
Thibodeau (2014) 11 0.40 -0.22, 1.01 - - - - 
Total 27 -0.57 -2.48, 1.34 -0.58 0.56 
16.09 (1) 
p<0.001 
93.78% 
Hearing aids+Bluetooth system vs. Hearing aids alone 
Kim et al (2014) 30 -3.77 -4.79, -2.75 - - - - 
Rodemerk & Galster (2015) 16 -2.20 -3.11, -1.29 - - - - 
Total 46 -2.97 -4.50, -1.43 -3.79 <0.001 
5.08 (1) 
p=0.024  
80.31% 
aMDs reported, as studies used the same outcome measure. SMDs are reported for all other meta-analyses. SMDs 
calculated as the mean difference between conditions divided by the by the standard deviation of the differences 
(within group).  
  
Table 2. Review authors’ judgements using Downs and Black (1998) checklist to assess study 
quality for each included study, whereby higher scores indicate superior study quality 
(total maximum score of 28). Risk of bias was assessed using the Cochrane risk of 
bias tool: A. sequence generation; B. allocation concealment C. blinding of 
participants and personnel; D. blinding of outcome assessors; E. incomplete outcome 
data; F. selective outcome reporting; G. other sources of bias.  
 
  
Study 
Study 
quality 
Risk of bias 
A B C D E F G 
Sacco et al (2016) 21 (good) High High High High Low  High Unclear 
Lewis et al (2004) 20 (good) High High High High Low High Unclear 
Lewis et al (2005) 20 (good) High High High Low Low High Unclear 
Chisolm et al (2007) 19 (fair) High High High Low Low High Unclear 
Lewis et al (2010) 18 (fair) High High High High Low High Unclear 
Rodemerk & Galster (2015) 16 (fair) High High High High Low  High Unclear 
Thibodeau (2014) 16 (fair) High High Low Low Low High Unclear 
Reed et al (2017) 15 (fair) High High High High Low Low Low 
Norrix et al (2016) 14 (poor) High High High High Low High Low 
Kim et al (2014) 13 (poor) High High High High Low  High Low 
Smith & Davis (2014) 13 (poor) High High High High Low High Unclear 
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Figure Legends 
 
Figure 1. Selection of studies for the systematic review based on Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. 
  
 
Figure 2. Summary of the random effects meta-analyses for speech intelligibility: A. PSAPs 
vs. unaided; B. Hearing aids+FM system vs. Unaided; C. Hearing aids+FM system vs. 
Hearing aids alone; D. Hearing aids+FM system vs. FM microphone only; E. Hearing 
aids+FM system vs. Hearing aids+2.4GHz system; F. Hearing aids+Bluetooth system 
vs. Hearing aids alone. Black squares = summery effect size of each study for speech 
intelligibility. Error bars = 95% confidence intervals (CI) for the summery effects. 
Diamond = overall effect size, lateral points indicate 95% CI for overall effect 
estimate. 
  
Supplemental 1. Full electronic search strategies for all databases. 
 
 
A. CINAHL 
S4 S1 AND S2 AND S3 
S3 ( (MH "Wireless Communications") OR (MH "Smartphone") OR (MH "Mobile Applications") ) OR TI 
Digital OR TI ( Alternative* or Premium or Smartphone* or "Smart Phone" or "Smart Phones" or iPhone or 
Wireless or "FM System" or "Frequency Modulation" or Bluetooth or "Assistive Listening" or "Mobile App" or 
"Mobile Apps" or "Mobile Application" or "Mobile Applications" or "Self-Fitting" ) OR AB ( Alternative* or 
Premium or Smartphone* or "Smart Phone" or "Smart Phones" or iPhone or Wireless or "FM System" or 
"Frequency Modulation" or Bluetooth or "Assistive Listening" or "Mobile App" or "Mobile Apps" or "Mobile 
Application" or "Mobile Applications" or "Self-Fitting" ) 
S2 ( (MH "Hearing Aids") OR (MH "Hearing Aid Fitting") ) OR TI ( ((Auditory or Hearing or Amplif* or 
Listening or Audible or Hearable or Aural or Audio*) and (Prosthes* or Device* or Aid or Aids or Product or 
Products)) or "Ear Mold" or "Ear Molds" or Conventional or Unaided or "No Treatment" or "Control Group" or 
"Usual Care" or "Waiting List" or Waitlist or "Treatment as Usual" or "Usual Treatment" or Routine or "Care as 
Usual" ) OR AB ( ((Auditory or Hearing or Amplif* or Listening or Audible or Hearable or Aural or Audio*) and 
(Prosthes* or Device* or Aid or Aids or Product or Products)) or "Ear Mold" or "Ear Molds" or Conventional or 
Unaided or "No Treatment" or "Control Group" or "Usual Care" or "Waiting List" or Waitlist or "Treatment as 
Usual" or "Usual Treatment" or Routine or "Care as Usual" ) 
S1 (MH "Mobile Applications") OR TI ( Hypoacus* or "Hearing Loss" or "Hearing Losses" or "Hearing 
Impairment" or "Hearing Impairments" or Deaf* or "Hearing Problem" or "Hearing Problems" ) OR AB ( 
Hypoacus* or "Hearing Loss" or "Hearing Losses" or "Hearing Impairment" or "Hearing Impairments" or Deaf* 
or "Hearing Problem" or "Hearing Problems" ) 
 
B. ClinicalTrials.Gov 
Advanced Search 
Conditions: Hearing OR Deafness 
Interventions: (Hearing OR Ear Mold OR Auditory OR Amplified OR Amplifier OR Listening OR Audible OR 
Hearable OR Aural OR Audio) AND (Device OR Devices Aid OR Aids OR Product OR Products) 
 
C. Cochrane Library 
#1 MeSH descriptor: [Hearing Loss] explode all trees 
#2 (Hypoacus* or "Hearing Loss" or "Hearing Losses" or "Hearing Impairment" or "Hearing Impairments" or 
Deaf* or "Hearing Problem" or "Hearing Problems"):ti,ab 
#3 #1 or #2 
#4 MeSH descriptor: [Hearing Aids] this term only 
#5 (((Auditory or Hearing or Amplif* or Listening or Audible or Hearable or Aural or Audio*) and (Prosthes* or 
Device* or Aid or Aids or Product or Products)) or "Ear Mold" or "Ear Molds" or Conventional or Unaided or 
  
"No Treatment" or "Control Group" or "Usual Care" or "Waiting List" or Waitlist or "Treatment as Usual" or 
"Usual Treatment" or Routine or "Care as Usual"):ti,ab 
#6 #4 or #5 
#7 MeSH descriptor: [Wireless Technology] explode all trees 
#8 MeSH descriptor: [Smartphone] explode all trees 
#9 MeSH descriptor: [Mobile Applications] explode all trees 
#10 Digital:ti 
#11 (Alternative* or Premium or Smartphone* or "Smart Phone" or "Smart Phones" or iPhone or Wireless or "FM 
System" or "Frequency Modulation" or Bluetooth or "Assistive Listening" or "Mobile App" or "Mobile Apps" or 
"Mobile Application" or "Mobile Applications" or "Self-Fitting"):ti,ab 
#12 #7 or #8 or #9 or #10 or #11 
#13 #3 and #6 and #12 
 
D. EMBASE 
1. Exp Hearing Impairment/ OR (Hypoacus* OR "Hearing Loss" OR "Hearing Losses" OR "Hearing 
Impairment" OR "Hearing Impairments" OR Deaf* OR "Hearing Problem" OR "Hearing Problems").ti,ab. 
2. Hearing Aid/ OR Air Conduction Hearing Aid/ OR Assistive Listening Device/ OR Exp Bone Conduction 
Hearing Aid/ OR Hearing Aid Analysis System/ OR Hearing Aid Calibrator/ OR Master Hearing Aid/ OR 
Tactile Hearing Aid/ OR Tinnitus Masker/ OR Transcutaneous Air Conduction Hearing Aid/ OR Wireless 
Air Conduction Hearing Aid/ OR (((Auditory OR Hearing OR Amplif* OR Listening OR Audible OR 
Hearable OR Aural OR Audio*) AND (Prosthes* OR Device* OR Aid OR Aids OR Product OR Products)) 
OR "Ear Mold" OR "Ear Molds" OR Conventional OR Unaided OR "No Treatment" OR "Control Group" 
OR "Usual Care" OR "Waiting List" OR Waitlist OR "Treatment as Usual" OR "Usual Treatment" OR 
Routine OR "Care as Usual").ti,ab. 
3. Wireless Communication/ OR Mobile Application/ OR Digital.ti. OR (Alternative* OR Premium OR 
Smartphone* OR "Smart Phone" OR "Smart Phones" OR iPhone OR Wireless OR "FM System" OR 
"Frequency Modulation" OR Bluetooth OR "Assistive Listening" OR "Mobile App" OR "Mobile Apps" OR 
"Mobile Application" OR "Mobile Applications" OR "Self-Fitting").ti,ab. 
4. Crossover-Procedure/ OR Double-Blind Procedure/ OR Randomized Controlled Trial/ OR Single-Blind 
Procedure/ OR Exp "Clinical Trial (Topic)"/ OR Exp Controlled Study/ OR Exp Cohort Analysis/ OR 
(Random* OR Factorial* OR Crossover* OR "Cross Over" OR Placebo* OR (Doubl* adj Blind*) OR (Singl* 
adj Blind*) OR Assign* OR Allocat* OR Volunteer*).mp. OR (Groups OR Nonrandomi?d OR Trial* OR 
"Quasi Experimental" OR Placebo OR RCT* OR "Before After" OR "Before and After" OR "CBA Study" 
OR "CBA Studies" OR Cohort OR Concurrent OR Incidence OR "Follow Up" OR Followup OR 
Longitudinal OR Prospective OR Retrospective OR "Case Control" OR "Case Comparison" OR "Case 
Compeer" OR "Case Base" OR Retrospective).ti,ab. 
5. 1 and 2 and 3 and 4 
 
E. ISRCTN 
Advanced Search 
  
Condition: Hearing 
 
F. MEDLINE 
Exp Hearing Loss/ OR (Hypoacus* OR "Hearing Loss" OR "Hearing Losses" OR "Hearing Impairment" OR 
"Hearing Impairments" OR Deaf* OR "Hearing Problem" OR "Hearing Problems").ti,ab. 
Hearing Aids/ OR (((Auditory OR Hearing OR Amplif* OR Listening OR Audible OR Hearable OR Aural OR 
Audio*) AND (Prosthes* OR Device* OR Aid OR Aids OR Product OR Products)) OR "Ear Mold" OR "Ear 
Molds" OR Conventional OR Unaided OR "No Treatment" OR "Control Group" OR "Usual Care" OR "Waiting 
List" OR Waitlist OR "Treatment as Usual" OR "Usual Treatment" OR Routine OR "Care as Usual").ti,ab. 
Exp Wireless Technology/ OR Exp Smartphone/ OR Exp Mobile Applications/ OR Digital.ti. OR (Alternative* 
OR Premium OR Smartphone* OR "Smart Phone" OR "Smart Phones" OR iPhone OR Wireless OR "FM System" 
OR "Frequency Modulation" OR Bluetooth OR "Assistive Listening" OR "Mobile App" OR "Mobile Apps" OR 
"Mobile Application" OR "Mobile Applications" OR "Self-Fitting").ti,ab. 
Exp Clinical Trials as Topic/ OR Exp Non-Randomized Controlled Trials as Topic/ OR Exp Cross-Over Studies/ 
OR Exp Controlled Before-After Studies/ OR Exp Cohort Studies/ OR Exp Case-Control Studies/ OR 
(Randomized Controlled Trial OR Controlled Clinical Trial OR Pragmatic Clinical Trial OR Clinical Trial OR 
Observational Study OR Multicenter Study).pt. OR (Randomi?ed OR Nonrandomi?d OR Randomly OR Placebo 
OR Trial* OR Groups).ab. OR Drug Therapy.fs. OR ("Quasi Experimental" OR Placebo OR RCT* OR "Cross 
Over" OR Crossover OR "Before After" OR "Before and After" OR "CBA Study" OR "CBA Studies" OR Cohort 
OR Concurrent OR Incidence OR "Follow Up" OR Followup OR Longitudinal OR Prospective OR Retrospective 
OR "Case Control" OR "Case Comparison" OR "Case Compeer" OR "Case Base" OR Retrospective).ti,ab. NOT 
(Animals NOT (Humans and Animals)).sh. 
1 and 2 and 3 and 4 
 
G. PubMed 
("Hearing Loss"[Mesh] OR Hypoacus*[tiab] OR "Hearing Loss"[tiab] OR "Hearing Losses"[tiab] OR "Hearing 
Impairment"[tiab] OR "Hearing Impairments"[tiab] OR Deaf*[tiab] OR "Hearing Problem"[tiab] OR "Hearing 
Problems"[tiab]) AND ("Hearing Aids"[Mesh:NoExp] OR ((Auditory[tiab] OR Hearing[tiab] OR Amplif*[tiab] 
OR Listening[tiab] OR Audible[tiab] OR Hearable[tiab] OR Aural[tiab] OR Audio*[tiab]) AND (Prosthes*[tiab] 
OR Device*[tiab] OR Aid[tiab] OR Aids[tiab] OR Product[tiab] OR Products[tiab])) OR "Ear Mold"[tiab] OR 
"Ear Molds"[tiab] OR Conventional[tiab] OR Unaided[tiab] OR "No Treatment"[tiab] OR "Control Group"[tiab] 
OR "Usual Care"[tiab] OR "Waiting List"[tiab] OR Waitlist[tiab] OR "Treatment as Usual"[tiab] OR "Usual 
Treatment"[tiab] OR Routine[tiab] OR "Care as Usual"[tiab]) AND ("Wireless Technology"[Mesh] OR 
"Smartphone"[Mesh] OR "Mobile Applications"[Mesh] OR Alternative*[tiab] OR Premium[tiab] OR Digital[ti] 
OR Smartphone*[tiab] OR "Smart Phone"[tiab] OR "Smart Phones"[tiab] OR iPhone[tiab] OR Wireless[tiab] OR 
"FM System"[tiab] OR "Frequency Modulation"[tiab] OR Bluetooth[tiab] OR "Assistive Listening"[tiab] OR 
"Mobile App"[tiab] OR "Mobile Apps"[tiab] OR "Mobile Application"[tiab] OR "Mobile Applications"[tiab] OR 
"Self-Fitting"[tiab]) AND ("Clinical Trials as Topic"[Mesh] OR Randomized Controlled Trial[pt] OR Controlled 
Clinical Trial[pt] OR Pragmatic Clinical Trial[pt] OR Clinical Trial[pt] OR Observational Study[pt] OR 
Multicenter Study[pt] OR "Non-Randomized Controlled Trials as Topic"[Mesh] OR Randomized[tiab] OR 
  
Randomised[tiab] OR Nonrandomized[tiab] OR Nonrandomised[tiab] OR "Quasi Experimental"[tiab] OR 
Placebo[tiab] OR Randomly[tiab] OR Trial[tiab] OR Trials[tiab] OR RCT*[tiab] OR Groups[tiab] OR "Cross-
Over Studies"[Mesh] OR "Cross Over"[tiab] OR Crossover[tiab] OR "Controlled Before-After Studies"[Mesh] 
OR "Before After"[tiab] OR "Before and After"[tiab] OR "CBA Study"[tiab] OR "CBA Studies"[tiab] OR 
"Cohort Studies"[Mesh] OR Cohort[tiab] OR Concurrent[tiab] OR Incidence[tiab] OR "Follow Up"[tiab] OR 
Followup[tiab] OR Longitudinal[tiab] OR Prospective[tiab] OR Retrospective[tiab] OR "Case-Control 
Studies"[Mesh] OR "Case Control"[tiab] OR "Case Comparison"[tiab] OR "Case Compeer"[tiab] OR "Case 
Base"[tiab] OR Retrospective[tiab]) 
 
H. WHO ICTRP 
Advanced Search 
Recruitment Status is All 
Condition: Hearing OR Deafness 
Intervention: (Hearing OR Ear Mold OR Auditory OR Amplified OR Amplifier OR Listening OR Audible OR 
Hearable OR Aural OR Audio) AND (Device OR Devices Aid OR Aids OR Product OR Products) 
 
 
  
Supplemental 2. Characteristics of included studies. FM = Frequency modulation; HA = 
Hearing aid; PTA = Pure tone average. 
 
Reference Participants  
Intervention/ 
comparator 
Outcomes 
Setting & 
design 
Follow-up 
duration(s) 
1. Personal sound amplification products (PSAPs) 
Reed et al (2017) 
USA  
N=42 (28 F; 14 M) 
Mean age = 71.6y 
Mean PTA = 35.4 dB HL 
Unaided 
Hearing aid (Oticon) 
PSAPs: 
(i) MSA 30X Sound Amplifier ($29.99 
USD) 
(ii) Tweak Focus ($269.99 USD) 
(iii) Etymotic BEAN ($299.99 USD) 
(iv) Soundhawk ($349.99 USD) 
(v) Sound World Solutions CS50+ 
($349.99 USD) 
Speech intelligibility: 
AZBio sentence-in-noise 
Task (Spahr et al., 2012) 
Clinical 
Before-after 
comparison 
Randomized 
order 
Immediately post-
comparison 
Sacco et al (2016) 
France 
N=31 (17 F; 14 M) 
Mean age=78.9y 
(SD=9.7) 
Mean PTA=47.74 dB HL 
Unaided 
TEO First  
Speech intelligibility: 
Speech audiometry in quiet 
and noise 
Hearing-specific QoL: 
Glasgow Hearing Aid Benefit 
Profile (Gatehouse, 1999) 
Listening ability: 
Glasgow Hearing Aid Benefit 
Profile (Gatehouse, 1999) 
Feasibility: 
Self-reported acceptability; 
Average daily time of use 
Adverse effects 
Clinical 
Before-after 
comparison 
  
1 month 
2. Remote microphone systems 
Chisolm et al (2007) 
USA 
N=36 (all M) 
Mean age= 79y (68-80) 
Mean PTA=69.7 dB HL 
Report no evidence of 
retro-cochlear pathology 
BTE digital or analogue hearing aids 
(Phonak) alone 
Hearing aids+FM system (Phonak 
Microlink) 
Hearing-specific QoL: 
MarkeTrak VI survey 
Listening ability: 
Client Oriented Scale of 
Improvement (Dillon et al., 
1997); Communication Profile 
for the Hearing Impaired 
(Demorest & Erdman, 1987) 
Clinical 
Before-after 
comparison 
  
6 weeks & 
1 year 
Kim et al (2014) 
South Korea 
N=30 (15 F; 15 M) 
Mean age= 57.2y (21-76) 
Mean PTA=33.17 dB HL 
Hearing aids+Bluetooth® system  
(BioSoundLab, Seoul, Korea): 
(i) conventional (i.e. free-field 
acoustic signal transmission) 
(ii) wireless mode (i.e. directed 
wireless speech signal transmission)  
Speech intelligibility: 
Word and sentence 
recognition (Jang et al., 2008) 
in quiet and noise. 
Laboratory 
Before-after 
comparison 
Immediately post-
comparison 
Lewis et al (2004) 
USA 
N=35 (17 F; 18 M) 
Median age= 73y (24-84) 
Mean PTA=43.1 dB HL 
Unaided 
BTE digital hearing aids (Phonak) 
alone: 
(i) omnidirectional mode 
(ii) directional mode 
Hearing aids+FM system (Phonak 
Microlink) 
(i) monaural 
(ii) binaural 
Speech intelligibility: 
Hearing In Noise Test 
(Nilsson et al., 1994)  
Clinical 
Before-after 
comparison 
Randomized 
order 
Immediately post-
comparison 
Lewis et al (2005) 
USA 
N=23 (10 F; 13 M) 
Median age= 73y (34-81) 
Mean PTA=55.2 dB HL 
BTE digital hearing aids alone 
(Phonak) 
Hearing aids+FM system (Phonak 
Microlink) 
Listening ability: 
Communication Profile for the 
Hearing Impaired (Demorest 
& Erdman, 1987) 
Clinical 
Before-after 
comparison 
Randomized 
order 
Experimenter 
blinding 
3 months 
  
Lewis et al (2010) 
USA 
N=10 (1 F; 9 M) 
Mean age= 72y (SD=9) 
Mean PTA=44.54 dB HL 
Unaided 
BTE digital hearing aids 
(Phonak)+FM system (Phonak 
Microlink): 
(i) 0 dB HA attenuation (i.e. equal 
output) 
(ii) 10 dB HA attenuation 
(iii) 20 dB HA attenuation 
(equivalent to FM-only) 
(iv) 30 dB HA attenuation 
(v) 40 dB HA attenuation  
Speech intelligibility: 
Hearing In Noise Test 
(Nilsson et al., 1994) 
Clinical 
Before-after 
comparison  
Randomized 
order 
Immediately post-
comparison 
Norrix et al (2016) 
N=10 (3 F; 7 M) 
Mean age= 49.6y 
(SD=14.1) 
Mean PTA=27.3 dB HL 
BTE digital hearing aids (Oticon)/FM 
system (Oticon Amigo): 
(i) FM-only 
(ii) HA+FM System 
Speech intelligibility: 
Bamford-Kowal-Bench 
Speech-in-Noise Test 
(Etymotic Research, 2005)  
Laboratory 
Before-after 
comparison 
Counterbalanced 
order 
Immediately post-
comparison 
Rodemerk & Galster (2015) 
USA 
N=16 (10 F; 6 M) 
Mean age= 56y 
(SD=18.9) 
Mean PTA=65.9 dB HL 
Uniaded 
BTE digital hearing aids (Phonak, 
Starkey, GN ReSound) alone 
Remote microphone systems only: 
(i) Bluetooth®/FM (Phonak) 
(ii) 900-MHz wireless (Starkey) 
(iii) 2.4 GHz wireless (GN ReSound) 
Hearing aids+ Remote microphone 
systems 
Speech intelligibility: 
Hearing In Noise Test 
(Nilsson et al., 1994)  
Laboratory 
Before-after 
comparison 
Randomized 
order 
Immediately post-
comparison 
Smith & Davis (2014) 
UK 
N=12 (4 F; 8 M) 
Mean age= 56y 
(SD=18.9) 
Mean PTA=65.9 dB HL 
Hearing aids alone (manufacturer not 
stated) 
Hearing aids+Bluetooth® accessories 
(streaming device, TV adaptor, 
remote control) 
Hearing-specific QoL: 
Glasgow Hearing Aid Benefit 
Profile (Gatehouse, 1999); 
International Outcome 
Inventory for Hearing Aids 
(Cox & Alexander, 2002) 
Listening ability: 
Glasgow Hearing Aid Benefit 
Profile (Gatehouse, 1999); 
International Outcome 
Inventory for Hearing Aids 
(Cox & Alexander, 2002); 
Speech, Spatial and Qualities 
of Hearing Scale (Gatehouse 
& Noble, 2004) 
Feasibility: 
Usability questionnaire 
Clinical 
Before-after 
comparison 
8 & 12 weeks 
Thibodeau (2014) 
USA 
N=11 (8 F; 3 M) 
Mean age=16-78y 
Mean PTA=58.4 dB HL 
Hearing aids(Phonak)+Remote 
microphone system: 
(i) Fixed FM 
(ii) Adaptive FM 
(iii) 2.4 GHz wireless 
Speech intelligibility: 
Hearing In Noise Test 
(Nilsson et al., 1994)  
Feasibility: 
Subjective report of preferred 
system 
Clinical 
Before-after 
comparison 
Randomized 
order 
Participant and 
experimenter 
blinding 
Immediately post-
comparison 
 
